Establishment and Characterization of a TFE3 -rearranged Renal Cell Carcinoma Cell Line (FU-UR-2) With the PRCC-TFE3 Fusion Transcript.
| Autor: | Ishiguro M; Department of Pathology Fukuoka University Hospital, Fukuoka, Japan; mishiguro@fukuoka-u.ac.jp., Fukushige T; Department of Pathology Fukuoka University Hospital, Fukuoka, Japan., Iwasaki H; Fukuoka University Faculty of Medicine, Fukuoka, Japan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Anticancer research [Anticancer Res] 2023 Aug; Vol. 43 (8), pp. 3463-3470. |
| DOI: | 10.21873/anticanres.16522 |
| Abstrakt: | Background/aim: Xp11.2-RCC was classified into molecularly defined renal carcinomas and named TFE3-rearranged renal cell carcinoma (TFE3-rRCC) in the 2022 World Health Organization classification of renal tumors. Materials and Methods: In this study, we established and characterized a TFE3-rRCC cell line from a right-sided renal tumor of a 35-year-old female patient and named it FU-UR-2. FU-UR-2 had been initially diagnosed as a papillary RCC because the patient was 35 years old, a routine immunohistochemical staining for TFE3 was negative, and its morphology was papillary. The G-band analysis revealed an X-chromosome aberration, thus we performed immunohistochemical re-staining for TFE3 and examined the aberration in the TFE3 gene by reverse-transcriptase polymerase chain reaction and fluorescence in situ hybridization. Results: FU-UR-2 was confirmed as a TFE3-rRCC with a PRCC-TFE3 fusion transcript. Conclusion: Cultured FU-UR-2 cells continuously propagated over 90 passages and may provide a new permanent culture model to study pathogenetic mechanisms, investigate biological behavior, and develop new treatments such as molecular-targeting antitumor agents or immunological drugs for TFE3-rRCCs. (Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|